Bayer Healthcare LLC

Bayer Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Direvo Biotechnology Ag

Christian Votsmeier

Jan Tebbe

Uwe Gritzan

Susanne Steinig

Peter Scholz

Zhuozhi Wang

Sandra Berndt

Nina Wobst

Joerg Birkenfeld

Ulrich Haupts

Junliang Pan

Andreas Scheidig

Simone Brückner

Beatrix Stelte-Ludwig

Michael Strerath

Ernst Weber

Mark Trautwein

Wayne Coco

Nikolaus Pawlowski

Sabine Hoff

Katharina Filarsky

Wiebke Maria Nadler

Helge Roider

Su-Yi Tseng

Kerstin Baral

Joanna Grudzinska

Hanna Plittersdorf

Klaus Pellengahr

Kornelia Kirchner

Patrick Jones

Simone Brueckner

Hans-Georg Lerchen

Anne-Sophie Rebstock

Yolanda Cancho Grande

Simone Greven

Sven Wittrock

Christoph Mahlert

Lisa Dietz

Joanna Grudzinska-Goebel

Ulrich Kettling

Stephan Märsch

Andre Koltermann

Dorian Schönfeld

Oliver Von Ahsen

Stefanie Hammer

Julian Marius Glück

Matyas Gorjanacz

Philipp Ellinger

Pascale Buchmann

Phaik Lyn Oh

Pedro Paz

Christian Bertling

Jenny Fitting

Jörg Birkenfeld

Wayne M Coco

Jan Tebe

Simone BRÜCKNER

The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human,and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.

Methods of treatment using CCR8 antibodies

The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.

CCR8 antibodies for therapeutic applications

The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies

Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.

Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)

Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNF&#x3b1;); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.

Antibodies to TNF&#x3b1;

The present invention provides engineered enzymes generated from protein scaffolds combined with Specificity Determining Regions, the production thereof and the use of said engineered enzymes for research, nutritional care, personal care and industrial purposes.

Engineered enzymes and uses thereof

Growing community of inventors

Cologne, Germany

Christian Votsmeier